OptiTROP-Lung06
What it tests: Sacituzumab tirumotecan + pembrolizumab vs chemo + pembrolizumab as first-line in PD-L1-negative non-squamous NSCLC
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.